Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers

NCT04500548 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04500548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04500548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Withdrawn
Start date
May 11, 2021
Completion date
June 21, 2022
Enrollment
0 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

constitutional mismatch repair deficiency syndrome, hematopoietic and lymphoid cell neoplasm, lynch syndrome, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent neuroblastoma, recurrent primary central nervous system neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory neuroblastoma, refractory primary central nervous system neoplasm, xeroderma pigmentosum